IV Product Cold Chain and Storage: What an Expiry Date Actually Certifies

In short: an expiry date is conditional, and the conditions are part of the product. A shelf life is measured against a climatic zone. WHO's current stability guidance sets the general long-term condition at 25 °C/60% RH, 30 °C/65% RH or 30 °C/75% RH — Zone II, Zone IVa and Zone IVb respectively — with the choice "determined by the climatic zone in which the FPP is intended to be marketed", plus accelerated testing at 40 °C/75% RH. "Stable" does not mean unchanged. The same guidance defines significant change as "a change from the initial content of API(s) of 5% or more detected by assay", so a passing study permits measurable loss. For oxidation-sensitive actives the container beats the fridge. In published parenteral nutrition work, ascorbic acid had a half-life of roughly 16 days at up to 40 °C in a six-layer bag, against 9 days at 4 °C and 29 hours at 40 °C in a three-layer one. And the common transit failure is cold, not heat — reviews of cold chain monitoring found below-range exposure in about a third of storage studies, no less often in higher-income countries than in lower-income ones. Once a bag is made up, European guidance puts unpreserved in-use storage at "normally not longer than 24 hours at 2 to 8 °C" unless it was prepared under controlled and validated aseptic conditions.

What an expiry date certifies

A shelf life is the output of a stability programme, and the programme has published rules. WHO's guidance sits in Technical Report Series No. 1010, Annex 10, issued in 2018 to replace the 2009 text in TRS 953, Annex 2; it runs alongside the ICH Q1 series.

For the general case the finished product is held at one of three long-term conditions — 25 °C ± 2 °C/60% RH ± 5%, 30 °C ± 2 °C/65% RH ± 5%, or 30 °C ± 2 °C/75% RH ± 5% — with at least twelve months of data at submission, and in parallel at an accelerated condition of 40 °C ± 2 °C/75% RH ± 5% for six months. Which long-term condition applies is not a manufacturer's preference. The guidance states it is determined by the climatic zone in which the product is intended to be marketed.

The second half of the definition is the part that rarely reaches a purchasing conversation. A stability study passes if no significant change occurs, and significant change for a finished product is defined as a fall of 5% or more in the assay of the active from its initial content, any degradation product exceeding its acceptance criterion, or failure to meet criteria for appearance, physical attributes, pH or functionality. A product inside its shelf life is therefore within a bounded loss. It is not guaranteed to be at full label content on the last day, and it was never claimed to be.

That has a direct consequence for how an assay figure should be read. A certificate of analysis reporting content at release describes the batch on the day it was tested. The number that matters for a buyer holding stock through a summer is the content at the end of shelf life, under the storage condition the product will actually see.

The guidance is also specific about labels, in a way that is useful as a screening test. It instructs that storage statements should be based on the stability evaluation, that "there should be a direct link between the storage statement on the label and the demonstrated stability of the FPP", and that terms such as "ambient conditions" or "room temperature" should be avoided. A carton whose only instruction is "store at room temperature" is using language the guidance tells manufacturers not to use.

Why a European dossier may not answer a Gulf question

Climatic Zone II is 25 °C/60% RH. Zone IVa is 30 °C/65% RH. Zone IVb is 30 °C/75% RH. ICH withdrew its own guideline on zone III and IV conditions in 2006 and left the definition to the respective regions and to WHO, and WHO records that several zone IV countries subsequently adopted the hotter, wetter condition in order to carry a larger safety margin.

WHO devotes an appendix to the consequence. Appendix 3 of Annex 10 is titled, in full, the interpretation of storage statements for products approved in climatic zone II when the products are to be distributed in zone IV. Its logic is that a statement must be read in the context of both the region of approval and the region of use. A product arriving in a zone IV country labelled "Store between 15 and 30 °C" would be expected to have demonstrated stability at zone IVa or IVb long-term conditions; where the stability was demonstrated at zone II conditions only, the appropriate storage statement for a zone IV region becomes "Do not store above 25 °C".

So the same product, unchanged, can lawfully carry a more permissive instruction in one market than in another. Nothing about the formulation differs. The data simply never covered the hotter condition, and the label in the destination market has to say so.

One qualification keeps this from being a blanket rule, and it is worth knowing because it changes the answer for a large part of the IV category. WHO notes that zone IVa may be acceptable in place of IVb where humidity is not an issue — for example, for storage in glass containers. Moisture-impermeable primary packaging largely removes the humidity half of the argument. It removes none of the temperature half.

For a Gulf buyer the practical question is therefore narrow and answerable: at which long-term condition was this product's shelf life established, for how long, and in which primary container? EFBA manufactures the IVIXIR series in its own GMP-certified facilities, and the manufacturer and wholesale page sets out how that supply side is organised. The general point holds regardless of supplier: a counterparty that moved the goods rather than made them usually cannot answer this question, because the dossier is not theirs.

The container outranks the refrigerator

Here the published evidence inverts the usual priority order, and it does so with numbers.

A 2005 study in the Journal of Parenteral and Enteral Nutrition measured ascorbic acid stability across parenteral nutrition bags of different wall construction. Oxygen permeability differed by more than three orders of magnitude: 0.5 mL O₂/m²/day in six-layer bags, 150 in three-layer resistant bags, and 1,500 in three-layer flexible bags. Ascorbic acid half-life followed the barrier, not the thermometer — about 16 days at up to 40 °C in the six-layer bag, against 9 days at 4 °C, 47 hours at 21 °C and 29 hours at 40 °C in the three-layer resistant bag.

Read those two series against each other. The barrier container sitting at 40 °C outlasted the permeable container sitting in a refrigerator, by a wide margin. The refrigerator was doing real work in the second case; it simply could not compensate for oxygen crossing the wall.

An earlier controlled prospective study from the same group, published in 2002, gives the same ordering at shorter timescales. Vitamin C half-life was 68.6 hours at 4 °C, 24.4 hours at 21 °C and 6.8 hours at 40 °C in multilayer bags, against 7.2, 3.2 and 1.1 hours in ethylvinyl acetate bags. Ten to thirty per cent of the vitamin C degraded within the first minutes after compounding, from residual oxygen already dissolved in the mixture. Vitamin B1 was stable at 21 °C but lost 43% over 72 hours at 40 °C in EVA bags.

These figures come from parenteral nutrition admixtures, and that limit should be stated rather than buried. Such mixtures contain amino acids, lipids and trace elements — copper among them — which catalyse ascorbate oxidation. A single active in a sealed glass ampoule is a different chemical system, and the half-lives do not transfer quantitatively. What transfers is the ranking: for an oxidation-sensitive molecule, container barrier first, temperature second, elapsed time third.

The actives this matters most for are predictable. Ascorbic acid and glutathione are redox-labile by design — the property being purchased is the property that degrades. Superoxide dismutase and lysozyme are proteins, where the failure mode is conformational rather than oxidative and freeze-thaw matters more than oxygen. A concept such as IVIXIR Sodium Ascorbate 7500 MD is specified around exactly this problem, and the honest way to assess one is to ask for stability data generated in the container that will actually be shipped.

What goes wrong in transit is usually cold

The regulatory frame for distribution is settled. EU Good Distribution Practice guidelines of 5 November 2013 require, in chapter 9, that defined storage conditions be maintained during transport, that delivery routes be risk-assessed to determine where temperature control is needed, and that excursions be reported to the distributor and recipient and investigated under a documented procedure. WHO's model guidance for time- and temperature-sensitive pharmaceutical products, TRS 961 Annex 9, supplies the operational detail through technical supplements on temperature mapping, qualification of storage areas and monitoring in transit.

Before treating a number as a failure, it is worth knowing what counts as one. USP General Chapter <659> defines controlled room temperature as 20 to 25 °C, allowing excursions between 15 and 30 °C provided the mean kinetic temperature remains at or below 25 °C. ICH Q1A(R2) defines mean kinetic temperature as a single derived temperature that, maintained over a period, gives the same thermal challenge as the range actually experienced; because degradation follows the Arrhenius relationship rather than a straight line, it sits above the arithmetic mean. A brief peak at 29 °C in a transit warehouse may well be within specification. A month whose MKT came out at 26 °C is not, even if the maximum never looked alarming.

The surprise is at the other end of the scale. A systematic review of cold chain monitoring published in Vaccine in 2007 found that between 14% and 35% of refrigerators or transport shipments had exposed vaccine to freezing temperatures, and that in studies examining all segments of distribution, between 75% and 100% of shipments were exposed at some point. A 2017 review in the same journal asked whether the problem had resolved and reported that it had not: below-range exposure appeared in 33% of storage studies from higher-income countries against 37.1% from lower-income ones, and in 38% of shipment studies from higher-income countries against 19.3% from lower-income ones.

That second comparison is the one to sit with. On the cold side, a wealthier supply chain was not a safer one — in shipments it was the worse of the two. Better equipment appears to solve the heat problem and then create a freezing problem, because an active cooler that is working hard is an active cooler that can overshoot.

These are vaccine studies, and the generalisation they support is about the distribution system rather than about any particular molecule. But it is the same couriers, the same airport handling and the same insulated boxes. For an intravenous product the consequences of freezing are concrete: salts precipitate, emulsions break, proteins denature, glass cracks at the shoulder. A vial that froze and thawed looks exactly like a vial that did not, until someone inspects it against light.

Which gives a small, cheap procurement rule. Ask for the time-temperature record for the consignment, and read the minimum, not only the maximum. A logger configured with a single upper alarm produces a record that cannot show you the failure that is statistically more likely.

Light: the exposure nobody logs

Temperature gets a data logger. Light gets a window blind, if that.

There is one piece of hard regulatory action here, and its scope should be reported precisely. On 2 September 2019 the marketing authorisation holders of parenteral nutrition products containing amino acids and/or lipids, in agreement with the MHRA and the EMA, issued a Direct Healthcare Professional Communication. It states that during administration to neonates and children below two years of age, such products should be protected from light — containers and administration sets — because exposure of these solutions to light causes formation of peroxides and other degradation products, and that premature neonates are at high risk of oxidative stress for several converging reasons. An ASPEN position paper in Nutrition in Clinical Practice in 2021 went further operationally, recommending complete photoprotection beginning during compounding and continued until the infusion is finished.

That is a neonatal measure, taken for a population with immature antioxidant defences, and it should not be presented as a general requirement for adult elective infusions. No regulator has imposed one. What does not depend on the patient is the chemistry: riboflavin is an efficient photosensitiser, and in a multivitamin mixture it drives the degradation of other components around it. A bag hanging for an hour in a treatment room with afternoon sun is losing content whoever is attached to it.

The buying question is therefore the modest one. Does the product's own stability data require protection from light; is that requirement met by the primary container, the secondary carton, or neither; and does it extend to the administration set? "Protect from light" on a label is a conclusion drawn from photostability testing under ICH Q1B. It is not a disclaimer.

Two clocks start when the bag is made up

From the moment a product is reconstituted or diluted, two independent limits apply, and the shorter one governs.

The microbiological limit is the better known. The European note for guidance on maximum shelf-life for sterile products after first opening or following reconstitution, CPMP/QWP/159/96, provides that an unpreserved sterile product — which includes preparations for infusion or injection — should from a microbiological point of view be used immediately; and that where it is not used immediately, in-use storage times and conditions prior to use would normally not be longer than 24 hours at 2 to 8 °C, unless reconstitution or dilution has taken place in controlled and validated aseptic conditions. That final clause is the whole of the difference between a treatment room and a licensed aseptic unit, expressed in one sentence.

WHO's in-use section covers the same ground for multidose containers more broadly, noting that a 30-day in-use period is normally considered acceptable without further supporting data. That default does not travel to an unpreserved infusion bag, and reading it as though it did is a recognisable error.

The chemical limit can be far shorter, and it belongs to the mixture rather than to the vial. The clearest demonstration in the literature is also one of the oldest. A 1981 study in the American Journal of Hospital Pharmacy examined thiamine in bisulfite-containing infusion solutions and found stability inversely related to pH; in an amino acid solution at pH 6.5, only 3% to 8% of the added thiamine remained after 24 hours at room temperature, and 37% after 24 hours at 7 °C. An antioxidant excipient present for an unrelated reason destroyed most of a B-complex vitamin inside a day, at a temperature no one would record as an excursion.

No temperature log would have caught that. Only a compatibility question would.

The conditions, the evidence, the purchase

Sorted by where in the chain the variable sits, with the published figure and what it implies for a purchase order.

When the consignment arrives

Five steps, in order. None of them is expensive; the first two are free.

One. Read the logger before the paperwork, and read both ends of it. Minimum, maximum, and the time spent outside range at each end. A record that reports only a peak has already discarded the more likely failure.

Two. Establish whether an excursion occurred in the regulatory sense rather than the colloquial one. Compare the record against the label statement, then compare the label statement against the condition the dossier was run at. Three documents, not one — and if the third is unavailable, that is itself the finding.

Three. Inspect against a defined list rather than a general impression: crystals or precipitate, which can indicate a freeze-thaw cycle; yellowing, which in an ascorbate preparation indicates oxidation; phase separation; container integrity at the shoulder and the closure; seal condition.

Four. Quarantine rather than shelve. The decision about whether an excursion affects a batch belongs to whoever holds the stability data, which is the manufacturer. Your contribution is the record of what happened. Send it, ask for a written release decision, and keep both documents together. EU GDP requires the excursion to be reported and investigated; a verbal reassurance is not an investigation.

Five. Then look at your own storeroom with the same eye. A dedicated, qualified refrigerator with a mapped temperature profile and a calibrated continuous logger is an inexpensive control. A general-purpose fridge with a dial thermometer generates no record at all, and the absence of a record is indistinguishable from the absence of control when someone later asks.

None of this is an argument for treating storage as a specialist discipline that sits outside purchasing. It is the opposite argument. Temperature, light and elapsed time are the only variables in the whole chain that change the product after it leaves the factory, and they are the ones a buyer can actually observe. EFBA's position here is a supply position rather than a clinical one: concepts such as IVIXIR To Infinity MD are defined sets of molecules at stated concentrations for professional use, not medicinal products and not treatments for any condition, and decisions about indication and setting belong to the practitioner. What a manufacturer can be held to is the specification and the evidence that it survived the journey. What can be specified can be assessed — and a storage condition is part of the specification, not a footnote to it.